



(ENGLISH VERSION)

COMUNICACION OF OTHER RELEVANT INFORMATION

December 27th 2022

In accordance with the provisions of article 226 of the consolidated text of the Securities Market Law, approved by Royal Legislative Decree 4/2015, of October 23, and other concordant provisions, ATRYS HEALTH, S.A. (“ATRYS” or the “Company”) communicates:

Purchase of 100% of Telmed SpA and Prestaciones Médicas e Inversiones Chaxa, SpA.

ATRYS announces that it has signed a purchase agreement for the acquisition of 100% of the company Telmed SpA and 100% of the company Prestaciones Médicas e Inversiones Chaxa, SpA (hereinafter both called “Chilerad”). Chilerad is a Chilean company dedicated to the provision of Teleradiology services in Chile that began its activity in the year 2008.

The aggregate price amounts to 8.05 million euros as fixed price, of which 7.43 million euros are paid in cash and 0.62 million euros are paid with the delivery of 103,879 shares at a price of 5.98 per share (through the delivery of ATRYS treasury shares) and variable payment (“earn out”) amounting to 0.85 euros linked to reaching a minimum EBITDA of 1.01 million euros in 2022.

It is estimated that Chilerad will end the 2022 financial year with a turnover of 5.7 million euros and an adjusted EBITDA of 1.01 million euros, without financial debt.

With this acquisition, ATRYS consolidates its position as a leading company in the provision of teleradiology diagnostic services in Chile.

It is estimated that the integration of Chilerad in the teleradiology operations of ATRYS in Chile will generate synergies in the amount of 0.4 million euros during the financial year 2023.

The closing of both acquisitions is subject to compliance with a series of usual conditions in this type of contract, expecting that the acquisition of Telmed SpA be carried out before December 31, 2022 and that of Prestaciones Médicas e Inversiones Chaxa, SpA during the first quarter of fiscal year 2023.

The information communicated has been prepared under the sole responsibility of the issuer and its directors.

Madrid, December 27, 2022

Mrs. Isabel Lozano Fernandez

CEO